Home › Funds › NEXTBio Capital Management LP › GPCR
NEXTBio Capital Management LP position in GPCR
STRUCTURE THERAPEUTICS INC · Health Care
NEXTBio Capital Management LP reported holding 312,496 shares of GPCR (STRUCTURE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$9.8M, representing 4.25% of its reported portfolio and ranking #10 among its reported holdings. NEXTBio Capital Management LP has disclosed GPCR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NEXTBio Capital Management LP's GPCR position evolved
NEXTBio Capital Management LP first disclosed a stake in GPCR in Q4 2025 at 94,443 shares (US$6.6M). The position peaked in Q2 2026 at 312,496 shares, worth US$16.8M. Across 4 filings, NEXTBio Capital Management LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 312,496 shares valued at US$9.8M. Notable position changes include a 41% increase in Q1 2026 (shares rose 11% over the following quarter), a 135% increase in Q2 2026 (shares fell 42% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 94.44K | $6.57M | New |
| Q1 2026 | 133.24K | $6.42M | Add |
| Q2 2026 | 312.50K | $16.77M | Add |
| Q3 2026 | 312.50K | $9.77M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GPCR and 13F data
GPCR (STRUCTURE THERAPEUTICS INC) is a Health Care company. 29 other funds we track also report a position in GPCR — the largest reported positions include Avoro Capital Advisors LLC (US$351.8M), Deep Track Capital, LP (US$254.4M), BVF INC/IL (US$180.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GPCR
- Avoro Capital Advisors LLC 6.56M sh · $351.84M · Q2 2026
- Deep Track Capital, LP 4.74M sh · $254.40M · Q2 2026
- BVF INC/IL 3.37M sh · $180.70M · Q2 2026
- ORBIMED ADVISORS LLC 2.21M sh · $118.58M · Q2 2026
- RTW INVESTMENTS, LP 1.61M sh · $86.27M · Q2 2026
- BAKER BROS. ADVISORS LP 1.43M sh · $76.88M · Q2 2026
- Casdin Capital 1.18M sh · $63.06M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.09M sh · $58.29M · Q2 2026
- Rock Springs Capital Management LP 640.32K sh · $34.37M · Q2 2026
- Siren, L.L.C. 872.97K sh · $27.30M · Q3 2026
- Logos Global Management LP 500.00K sh · $26.84M · Q2 2026
- Parkman Healthcare Partners LLC 485.66K sh · $26.07M · Q2 2026
More on NEXTBio Capital Management LP
FAQ
How long has NEXTBio Capital Management LP held GPCR?
NEXTBio Capital Management LP has disclosed GPCR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is NEXTBio Capital Management LP's current position in GPCR?
As of Q3 2026, NEXTBio Capital Management LP holds 312.50K shares of GPCR (STRUCTURE THERAPEUTICS INC), valued at $9.77M, representing 4.25% of its reported portfolio and ranking #10.
Has NEXTBio Capital Management LP been buying or selling GPCR?
In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP held unchanged its position in GPCR. The position peaked in Q2 2026 at 312.50K shares.
Which other funds hold GPCR?
Other major institutional holders of GPCR include Avoro Capital Advisors LLC, Deep Track Capital, LP, BVF INC/IL, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.